搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Sialic acid-binding Ig-like lectin 9(SIGLEC9) ELISA kit

Human Sialic acid-binding Ig-like lectin 9(SIGLEC9) ELISA kit

  • 中文名稱：
    人唾液酸結(jié)合Ig樣凝集素9(SIGLEC9)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL021303HU
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人唾液酸結(jié)合Ig樣凝集素9(SIGLEC9)酶聯(lián)免疫試劑盒（CSB-EL021303HU）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿，組織勻漿.樣本中的SIGLEC9含量。SIGLEC9是唾液酸結(jié)合免疫球蛋白樣凝集素家族成員，廣泛分布于免疫細(xì)胞表面。它能識(shí)別細(xì)胞表面糖基配體，參與免疫信號(hào)傳導(dǎo)，調(diào)控免疫細(xì)胞活性和功能。當(dāng)前圍繞其展開(kāi)多項(xiàng)研究，旨在明晰機(jī)制，為免疫相關(guān)疾病治療提供潛在靶點(diǎn)。試劑盒檢測(cè)范圍為125 pg/ml-8000 pg/ml，適用于科研場(chǎng)景中探究SIGLEC9在免疫應(yīng)答、疾病模型或病理狀態(tài)下的動(dòng)態(tài)變化，例如通過(guò)檢測(cè)不同處理?xiàng)l件下細(xì)胞培養(yǎng)上清、實(shí)驗(yàn)動(dòng)物體液或疾病相關(guān)組織樣本中的蛋白濃度，為免疫調(diào)控機(jī)制、生物標(biāo)志物篩選等基礎(chǔ)研究提供可靠數(shù)據(jù)支持。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書(shū)。
  • 別名：
    CD329 ELISA Kit; CDw329 ELISA Kit; FOAP 9 ELISA Kit; OB binding protein like ELISA Kit; OBBP LIKE ELISA Kit; Protein FOAP 9 ELISA Kit; Protein FOAP-9 ELISA Kit; sialic acid binding Ig like lectin 9 ELISA Kit; Sialic acid-binding Ig-like lectin 9 ELISA Kit; Sialic acid-binding immunoglobulin like lectin 9 ELISA Kit; SIGL9_HUMAN ELISA Kit; Siglec 9 ELISA Kit; Siglec-9 ELISA Kit; SIGLEC9 ELISA Kit
  • 縮寫：
    SIGLEC9
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum,plasma,tissue homogenates.
  • 檢測(cè)范圍：
    125 pg/ml-8000 pg/ml
  • 靈敏度：
    31.25 pg/ml
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Immunology
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度：

    To assess the linearity of the assay, samples were spiked with high concentrations of human SIGLEC9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

    　

    Sample

    Serum(n=4)

    1:1

    Average %

    95

    Range %

    88-102

    1:2

    Average %

    87

    Range %

    83-92

    1:4

    Average %

    92

    Range %

    88-97

    1:8

    Average %

    89

    Range %

    85-95

  • 回收率：

    The recovery of human SIGLEC9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    90

    85-96

    EDTA plasma (n=4)

    96

    90-102

  • 標(biāo)準(zhǔn)曲線：

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    pg/ml

    OD1

    OD2

    Average

    Corrected

    8000

    2.169

    2.234

    2.202

    2.068

    4000

    1.378

    1.297

    1.338

    1.205

    2000

    0.831

    0.828

    0.829

    0.696

    1000

    0.474

    0.489

    0.481

    0.348

    500

    0.383

    0.361

    0.372

    0.239

    250

    0.250

    0.253

    0.251

    0.118

    125

    0.186

    0.184

    0.185

    0.052

    0

    0.137

    0.129

    0.133

    　

  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.
  • 基因功能參考文獻(xiàn)：
    1. The SIGLEC9 rs2075803 G/rs2258983 A haplotype, which corresponds to a Siglec-9 variant that is less effective at suppressing inflammatory response, may be a risk factor for the development of emphysema. PMID: 27878892
    2. Glycophorin A, the most abundant sialoglycoprotein on erythrocytes, engaged neutrophil Siglec-9, a sialic acid-recognizing receptor known to dampen innate immune cell activation. These studies demonstrate a previously unsuspected role for erythrocytes in suppressing neutrophils ex vivo and in vitro and help explain why neutrophils become easily activated after separation from whole blood. PMID: 28416510
    3. Data suggest that sialic acid-binding Ig-like lectin-9 (Siglec-9)may serve as a potential diagnostic and therapeutic target for rheumatoid arthritis (RA). PMID: 28273363
    4. The mechanism of the Siglec-9 and AOC3 interaction is mediated both by protein-sugar interactions via the V domain and by the protein-protein interactions via the C22 Siglec9 domain. PMID: 27893774
    5. This work defines a critical role for aberrantly glycosylated MUC1 and identifies an activating pathway that follows engagement of Siglec-9. PMID: 27595232
    6. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages. PMID: 26923638
    7. Ligands for Siglec-8 and Siglec-9 may regulate the function of eosinophils, mast cells, neutrophils, and other cells in sinus mucosa. PMID: 26694037
    8. Inflammation results in up-regulation of immuneinhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. PMID: 25747723
    9. a polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients PMID: 25225409
    10. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. PMID: 24882272
    11. Protein degradation of focal adhesion kinase and related molecules was induced by Siglec-9 binding to its counterreceptors via sialylglycoconjugates, leading to the modulation of adhesion kinetics of cancer cells. PMID: 24145038
    12. Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway. PMID: 24045940
    13. The Siglec-9 peptide binding to the enzymatic groove of VAP-1 can be used for imaging conditions, such as inflammation and cancer. PMID: 21821708
    14. Siglec-9 A391C was the only polymorphism related to TCR-mediated signaling in human Siglec-9, resulting in less inhibition compared to the wild type. PMID: 20733319
    15. These results suggest that Siglec-9 expressed on DCs is involved in immunoregulation through ligation with mucins in an epithelial cancer patient. PMID: 20971061
    16. MUC16-Siglec-9 binding likely mediates inhibition of anti-tumor immune responses. PMID: 20497550
    17. Septic shock patients exhibit different ex vivo death responses of blood neutrophils after Siglec-9 ligation early in shock. PMID: 19295491
    18. Binding studies on recombinant human Siglec-9 show recognition of both Neu5Ac and Neu5Gc; in striking contrast, chimpanzee and gorilla Siglec-9 strongly prefer binding Neu5Gc. PMID: 14693915
    19. Siglec-9 can inhibit Fc epsilon receptor I-mediated serotonin release from rat basophilic leukemia cells and recruit the tyrosine phosphatases SHP-1 and SHP-2. PMID: 15557178
    20. data suggest that apoptotic (ROS- and caspase-dependent) and nonapoptotic (ROS-dependent) death pathways are initiated in neutrophils via Siglec-9 PMID: 15827126
    21. Siglecs-9 did not interact with sulfate derivatives of LacNAc and sulfated oligosaccharides containing sialic acid. PMID: 16732727
    22. The Siglec-9 provides not only a useful marker for certain subsets of AML, but also a potential therapeutic target. PMID: 16828866
    23. These results demonstrate that Siglec-9 enhances the production of the anti-inflammatory cytokine IL-10 in macrophages. PMID: 18325328
    24. A review of the cytotoxic effects of natural anti-Siglec9 autoantibodies on both neutrophils and eosinophils. PMID: 18558361
    25. Increased bacterial survival are also facilitated by group b Streptococcus sialylated capsular polysaccharide interactions with Siglec-9. PMID: 19196661
    26. Data suggest that age-specific interactions between Siglec-9 and SHP-1 may influence the altered inflammatory responsiveness and longevity of neonatal polymorphonuclear neutrophils. PMID: 19542910

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Membrane; Single-pass type I membrane protein.
  • 蛋白家族：
    Immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family
  • 組織特異性：
    Expressed by peripheral blood leukocytes (neutrophils and monocytes but not eosinophils). Found in liver, fetal liver, bone marrow, placenta, spleen and in lower levels in skeletal muscle, fetal brain, stomach, lung, thymus, prostate, brain, mammary, adre
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 10878

    OMIM: 605640

    KEGG: hsa:27180

    STRING: 9606.ENSP00000413861

    UniGene: Hs.245828